Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

A Phase 3 study of LY3484356 vs Investigator's choice of endocrine therapy in Breast Cancer

A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy

For more information:

https://clinicaltrials.gov/ct2/show/NCT04975308?cond=A+Randomized%2C+Open-Label%2C+Phase+3+Study+of+LY3484356+vs+Investigator%E2%80%99s+Choice+of+Endocrine+Therapy%2C+in+Patients+with+Estrogen+Receptor+Positive%2C+HER2+Negative+Locally+Advanced+or+Metastatic+Breast+Cancer+Previously+Treated+with+Endocrine+Therapy&draw=2&rank=1